About US
Contact us
-
Forxiga Receives Regulatory Approval in Japan for the Treatment of Type 2 DiabetesAstraZeneca today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Forxiga (dapagliflozin in 5 and 10 mg tablets), a sodium-glucose cotransporter 2 (SGLT2) inhibitor,2014/3/25
-
Biogen's haemophilia B therapy Alprolix approved in CanadaUS-based Biogen Idec has received approval from Health Canada for Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine pro2014/3/25
-
Five Prime and BMS partner to discover new immuno-oncology therapiesFive Prime Therapeutics and Bristol-Myers Squibb (BMS) have signed an agreement to discover, develop and commercialise immuno-oncology therapies directed toward targets identified in two undisclosed i2014/3/24
-
Sanofi Pasteur and SK Chemical to jointly develop pneumococcal conjugate vaccineSanofi Pasteur, the vaccines division of French pharmaceutical firm Sanofi, has entered into a long-term strategic cooperation with SK Chemicals to jointly develop a new pneumococcal conjugate vaccine2014/3/24
-
FDA approves Pierre Fabre's paediatric drug Hemangeol to treat infantile hemangiomaThe US Food and Drug Administration (FDA) has granted marketing authorisation to Pierre Fabre's paediatric drug Hemangeol (propranolol hydrochloride), as the first and only approved treatment for prol2014/3/21
-
ThromboGenics' vitreomacular traction drug Jetrea gets approval in SwitzerlandBelgium-based biopharmaceutical firm ThromboGenics has received approval from the Swiss Agency for Therapeutic Products, Swissmedic, for Jetrea (ocriplasmin) to treat adults with vitreomacular tractio2014/3/21
-
Merck's NOXAFIL injection secures US FDA approvalThe US Food and Drug Administration has approved Merck's antifungal agent NOXAFIL (posaconazole) injection (18mg/ mL), a new formulation for intravenous (IV) use. The antifungal agent is also markete2014/3/20
-
Medivation, Astellas ask FDA to approve Xtandi for pre-chemo prostate cancer useTheprostate cancerdrugXtandihas been a quick starter from, well, the start. TheFDAapproved it three months ahead of schedule in 2012 for men who have already had chemo. A study on pre-chemo cases was2014/3/20
-
Novartis receives clinical recommendation in Australia for meningitis B vaccineNovartis has received clinical recommendation from the Australian Technical Advisory Group on Immunisation (ATAGI) for its Bexsero meningococcal group B vaccine (rDNA, component, adsorbed) for use in2014/3/19
-
TaiGen’s pneumonia antibiotic Taigexyn gets marketing approval in TaiwanTaiGen Biotechnology Company (TaiGen) has received approval from the Taiwan Food and Drug Administration (TFDA) for its new drug application of Taigexyn oral formulation to treat community-acquired ba2014/3/19